NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia® Names Joyce A. O’Shaughnessy, MD as New Principal Investigator for FLEX Study
Renowned breast oncologist and clinical researcher to lead ongoing efforts to accelerate diagnostic discoveries and enable precision oncology through real-world evidence-based study platform
Read MoreNew Neoadjuvant Trial (MINT) Confirms the Predictive Utility of MammaPrint + BluePrint
The newly published prospective Multi-Institutional Neoadjuvant Therapy MammaPrint Project I (MINT) trial is the first neoadjuvant study to show that nodal downstaging in response to neoadjuvant therapy can be predicted by MammaPrint + BluePrint, Agendia’s advanced genomic assays.
Read MoreAgendia Appoints Ronald Andrews and David Schreiber to Board of Directors
Agendia, Inc., a gene expression profiling company advancing personalized early-stage breast cancer care, today announced the appointment of industry veterans Ronald (Ron) Andrews and David Schreiber to the company’s Board of Directors.
Read More